The share of MolMed takes off in Piazza Affari, rising by 7,99% at mid-morning, to 0,743 euros per share. The announcement, arrived this morning, of the enrollment of the first patient in the United States for theclinical trial expansion Phase III registration (TK008) of TK cell gene therapy in patients with high-risk leukemia.
The study is already underway in Europe and will count on patients enrolled in 16 clinical centers across the Old Continent, the USA and Israel. The president and CEO of MolMed Claudio Bordignon enthusiastically commented on the news: "The treatment of the first patient in the United States with TK cells opens a new frontier for the diffusion of MolMed's technology".
